Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBI-AD: Dabrafenib and Trametinib in Adjuvant Melanoma
NCT01682083Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2013
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 25
01
Overview
A Phase 3 trial of dabrafenib + trametinib, trametinib in melanoma, sponsored by Novartis. Started Jan 2013; status: completed.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01682083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01682083.